A NOVEL METHOD TO TREAT ALZHEIMER’S DISEASE AND TUMOR METASTASIS
Alzheimer’s disease (AD) is the most common age-associated dementia. It is a progressive neurodegenerative disorder that correlates with the accumulation of abnormally aggregated amyloid beta (Ab) in the brain. Current therapeutic options do not treat the underlying disease and have several side …
NOVEL METHOD TO SPECIFICALLY INHIBIT CATHEPSIN K COLLAGENOLYTIC ACTIVITY
Bone homeostasis is a complex process and requires a balance between bone formation and resorption. Cathepsin K is a collagenase which is highly expressed in bone resorbing cells and its deficiency leads to pycnodysostosis, a rare disease characterized by a decrease in …
DNA LOCK™: A NOVEL AND SECURE DNA-BASED AUTHENTICATION METHOD
Seized, counterfeit goods in the United States in 2012 were estimated to be worth over $1.30 billion. Current marking techniques can be recovered, copied and illegally used to mark counterfeited goods. To control this increasing problem, reliable counterfeit-resistant techniques are required. Scientists …
Harlem Biospace – Biotech Venture Summer Associate
Harlem Biospace(Hb) is a biotech incubator for New York City offering affordable shared wet-lab space for early-stage biotech companies. We have built a centrally located lab outfitted with modern biotech equipment, host unique classes and events, and provide business support – creating …
DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease
February 18, 2014– DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the …
Mount Sinai Genetic Testing Laboratory Launches More Accurate Carrier Screening Test for Spinal Muscular Atrophy
February 11, 2014 – The Icahn School of Medicine at Mount Sinai today announced the launch of a more accurate carrier screening test for spinal muscular atrophy (SMA), one of the most common and severe autosomal recessive disorders. This new test will help prospective …
Repurposing Drugs for Alzheimer’s Disease and Related Dementias Request for Proposals (RFP)
Neurodegenerative diseases represent one of the most difficult classes of diseases for which to develop drugs, yet the need is great with nearly 36 million people currently suffering from Alzheimer’s disease and related dementias worldwide. There are many different pathways that influence …
Single microRNA powers motor activity: Findings have implications for treating severe treatment-refractory epilepsy, says Mount Sinai researcher
December 5, 2013 – New research from the Icahn School of Medicine at Mount Sinai shows that microRNA-128 is one of the strongest regulators of nerve cell excitability and motor activity, and that it does so by adjusting an entire neuronal signaling …
Berg and Icahn School of Medicine at Mount Sinai Announce R&D Partnership for Drug Discovery and Development
October 10, 2013 – Berg, a biopharmaceutical company committed to a data-driven, biological research approach and the Icahn School of Medicine at Mount Sinai announced today a pharmaceutical and diagnostic R&D partnership that will leverage the power of multi-omic biology and data …
Dual Therapeutics, a New Oncology Start-up, is Launched by BioMotiv and the Icahn School of Medicine at Mount Sinai
October 9, 2013 – BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung …